Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
National Institutes of Health Clinical Center (CC)
Cancer Research UK
China-Japan Friendship Hospital
Cancer Research UK
Massive Bio, Inc.
Incyte Corporation
Stanford University
BerGenBio ASA
Stanford University
Haihe Biopharma Co., Ltd.
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Fore Biotherapeutics
Celgene
University of Wisconsin, Madison
Incyte Corporation
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)